Skip Navigation

InnovAiT 2008 1(9):631-641; doi:10.1093/innovait/inn118
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Men’s Health. Volume 1, Issue 9....
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bolland, W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the RCGP. All rights reserved. For permissions please e-mail: journals.permissions@oxfordjournals.org

Benign prostatic hypertrophy

Dr Will Bolland

General Practitioner, Leeds

E-mail: will.bolland{at}doctors.org.uk


  Abstract

The prevalence of symptomatic benign prostatic hypertrophy (BPH) in Europe varies from 14% for men in their fourth decade to more than 40% in their sixth. Assuming an overall prevalence of symptomatic BPH of 30%, in the UK, would mean that approximately 4 million men aged more than 40 years suffer from the condition.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.